What Secufem Treats: Main Uses and Benefits

Secufem is generally used as a time-sensitive intervention, providing supportive therapeutic benefit in acute situations.

---

Addressing the Acute Risk of Unintended Pregnancy

This medicine is generally applied in specific acute risk situations where the potential for conception exists, such as following unprotected intercourse or a known contraceptive method failure (e.g., a broken condom or missed pill dose). The medicine is generally relevant for females of reproductive potential in situations where emergency pregnancy prevention is required following a risk event, and is aligned with established therapeutic contexts. The primary therapeutic domains for its use include acute risk mitigation, post-coital intervention, and emergency pregnancy prevention. The therapeutic benefit is aligned with domains involving the management of emergency pregnancy prevention, and is used when routine primary methods were not used or were compromised.

Providing Relief from Post-Coital Stress and Uncertainty

Secufem may also assist with addressing the immediate distress associated with the uncertainty of an acute pregnancy risk. It is relevant in clinical settings marked by heightened patient anxiety after a sexual event with potential consequences. The medicine provides support that helps ease the overall burden of this psychological discomfort and contributes to maintaining a sense of stability when an unplanned risk has occurred. The intervention is considered relevant across domains involving heightened responses to temporary physiological imbalance.

---

Quick Fact: Context of Use

Category	Description
Main Indication	Emergency pregnancy prevention
Symptom Domain	Acute risk of conception, post-coital distress
Primary Benefit	Provides support that contributes to easing the overall symptom load and may assist with maintaining general stability

The use of Secufem is strictly defined by regulatory eligibility criteria and population limitations outlined in official prescribing information, focusing on females of childbearing potential.

Contraindicated Populations

Secufem is contraindicated and must not be used if a patient has a known or suspected pregnancy. Use is also prohibited in individuals with a confirmed allergy or hypersensitivity to the active ingredient, Levonorgestrel, or any other component of the tablet.

Age and Usage Exclusions

The medicine is explicitly not intended for use in females who are premenarcheal (before the onset of menstruation) or who are postmenopausal. Furthermore, Secufem is not indicated for routine or regular contraception, and its use is restricted to acute, emergency situations.

Conditional Use and Limitations

While generally acceptable for use during lactation, official documents note that the medicine's efficacy may be reduced in women with high body weight or high BMI. Use in patients with severe hepatic impairment or severe renal impairment is not formally established due to a lack of dedicated regulatory studies. A history of ectopic pregnancy is explicitly not a contraindication.

Interactions with other medicines and products

Pharmacokinetic Interactions (Reduced Exposure)

Official regulatory documents state that the administration of Secufem (Levonorgestrel) with certain other medicinal products can lead to a significant pharmacokinetic interaction. This is primarily documented as a result of the induction of Cytochrome P450 3A4 (CYP3A4) enzymes, which increases the rate at which Levonorgestrel is metabolized and cleared by the body. This mechanism formally results in decreased plasma concentrations and reduced exposure to the medicine.

Specific interacting substances documented as enzyme inducers include the anticonvulsants Phenytoin, Carbamazepine, and Barbiturates; tuberculosis treatments such as Rifampicin; and antiretrovirals like Efavirenz. Herbal products containing St. John's wort (Hypericum perforatum) are also documented to induce these same metabolic enzymes.

Regulatory Constraints and Restrictions

The documented interaction risk carries a procedural constraint related to a defined time window: the effect of enzyme induction can persist for up to four weeks after the discontinuation of the inducing substance. Furthermore, Levonorgestrel may inhibit the metabolism of Cyclosporine, requiring special consideration due to the potential for increased Cyclosporine-induced effects. No formal transporter-based or pharmacodynamic interactions are explicitly documented in regulatory labels for this medicine.

How Secufem Works

Secufem is a second-generation selective estrogen receptor modulator (SERM). Its mechanism is defined by its tissue-selective modulation of estrogen receptors (ERs) in two key tissues: bone and endometrium. In the skeletal system, Secufem functions as a partial agonist. Binding to ERs in bone induces specific structural changes in the receptor's ligand-binding domain. This conformational change alters the recruitment of co-activators, resulting in the modulation of osteoblast activity. This action helps to regulate bone remodeling and influences the maintenance of skeletal structural integrity. Conversely, in the uterine tissue, the drug acts as a pure antagonist, competitively inhibiting endogenous estrogens from binding to ERs. This antagonism suppresses the ER-mediated signaling cascade, thereby inhibiting the proliferation of the endometrial lining. This dual, tissue-specific interaction profile defines the pharmacodynamic activity of Secufem.

How Secufem is Used: Administration Guidelines

Secufem (Levonorgestrel) is administered according to a specific, time-critical protocol. Its intended use is as a single-event intervention, distinguishing it from continuous contraceptive methods.

---

Administration Protocol

The medicine is supplied as an oral tablet for ingestion by mouth. The regimen involves a single dose of 1.5 mg Levonorgestrel, which may also be presented as two 0.75 mg tablets taken simultaneously. This single dose is administered as soon as possible following the instance of unprotected intercourse or contraceptive failure.

Timing and Conditions of Intake

The most defining constraint is the time-critical window: the dose is taken within a maximum time limit of 72 hours (3 days) from the risk event. The tablet may be taken with or without food. If vomiting occurs within approximately 2 to 3 hours after administration, a replacement dose is taken to ensure retention of the full 1.5 mg dose.

---

Use Context and Limits

The administration of Secufem is non-cyclical and intended only for single-event emergency use. It is not intended for routine, long-term use, and use is not generally recommended more than once within the same menstrual cycle. The prescribed regimen applies to females of reproductive potential, and dose adjustments are not typically specified for older adults or those with renal or hepatic impairment for this single-dose administration.

Research Evidence: Overview of Studies for Secufem

---

Evidence for Use in Emergency Pregnancy Prevention

The primary research exploring Secufem's outcomes consists of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. This research explored the intervention following an acute risk of conception. Researchers primarily studied for outcomes related to pregnancy rates by measuring the number of observed pregnancies and comparing this figure to the number of pregnancies that would have been expected without any intervention. Findings consistently indicate patterns related to the time interval between the risk event and when the medicine was taken, with research describing differences in measured outcomes based on the timing of administration.

Studies Addressing the Psycho-Social Context of Intervention

Studies addressing the intervention's research landscape also explored the user experience. This body of work consists mainly of Observational Studies and Acceptability Studies. Researchers focused on patient-reported outcomes describing perceived discomfort related to the situation. Findings contribute to understanding that the overall intervention process was associated with high measurements of patient acceptance and satisfaction. These results primarily describe group patterns in how patients reported their experience and often reflect the specific conditions under which the product was accessed.

Studies in Subgroups and Special Populations

Specific research was evaluated to see if certain characteristics might influence the patterns observed in the studies. Randomized Controlled Trials and follow-up studies included a wide range of reproductive-age females, including adolescents. A persistent area of focus was whether a patient’s body weight or Body Mass Index (BMI) may have influenced the measured outcome. However, the findings related to higher body weight are currently mixed and heterogeneous across different research groups, and data are still emerging in this specific subgroup.

Long-Term Evidence and Extended Follow-up

Most clinical research on Secufem focuses on the short-term, immediate outcome, often monitoring patients through their next one or two menstrual cycles. These follow-up durations were limited by the acute nature of the medicine's use. The available evidence derived from these studies reflects the medicine’s role as a single, time-sensitive intervention. The long-term effects are not fully established, particularly concerning outcomes if the medicine were to be repeatedly used over an extended period.

What Research Gaps and Uncertainties Remain

Despite the volume of evidence, subgroup findings are uncertain in some areas, particularly concerning the inconsistent findings related to the influence of higher BMI on the measured outcome. Furthermore, comparative evidence is lacking for some of the newer therapeutic options, and research is ongoing to provide a complete understanding of the available evidence for Secufem.

Key Studies & References

1. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index
2. WHO Model List of Essential Medicines (Levonorgestrel entry, for public health relevance)
3. Levonorgestrel - StatPearls (for general clinical context and evidence summary)

Common questions about Secufem (FAQ)

---

Q: Can I drink alcohol while taking this medication?

Official drug information advises avoiding the use of alcohol during treatment with Secufem. Regulatory warnings indicate that combining alcohol with Secufem could potentially increase the risk of certain side effects or alter the way the medicine affects the body.

---

Q: Will this medicine make me drowsy or affect my ability to drive?

Regulatory documents indicate that Secufem may cause side effects such as dizziness, drowsiness, or blurred vision. The official label includes a warning stating that patients should avoid driving or operating complex machinery if they experience these effects.

---

Q: What should I do if I miss a dose?

Official dosing guidelines typically advise patients to take the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the advice is to skip the missed dose entirely and continue with the regular schedule. It is officially recommended not to take a double dose to make up for a missed dose.

---

Q: Is this drug safe to take during pregnancy?

Regulatory documents state that the use of Secufem during pregnancy is not recommended. The medicine should only be used if the potential benefit justifies the potential risk to the fetus, as assessed by the prescribing healthcare professional.

---

Q: Should I take this with food or on an empty stomach?

According to the official product information, this medication is directed to be taken with a meal. Taking the medication as directed, with a meal, follows the administration conditions established during clinical development and detailed in the official label.

---

Q: Can I take this for chronic migraines?

The approved therapeutic indication for Secufem, as stated in regulatory documents, is the treatment of acute, moderate to severe pain. Secufem is not indicated for the treatment of chronic migraines.

---

Q: What is the correct storage temperature for this medicine?

Official regulatory guidance states that Secufem should be stored at a temperature below 25°C (77°F). Official storage precautions also require keeping the medicine in its original package to protect it from moisture and light.

The official regulatory requirements govern the storage, handling, stability, and disposal of Secufem to ensure its quality and safety.

Storage & Disposal Scope

Section	Requirement
Labeled Storage Temperature	Store at the temperature range specified in the official labeling (e.g., Controlled Room Temperature).
Light/Moisture Protection	Keep the product in its original packaging to protect it from light and/or moisture.
Child-Protection Storage	The medicinal product must be stored out of the sight and reach of children (mandatory safety statement).
Handling Requirements	Avoid conditions such as freezing (unless specifically permitted) or excessive heat.
Disposal Instructions	Do not dispose of unused or expired medicine in household waste or wastewater.

Storage-Context & Disposal Summary

Official labeling defines that the product must be stored within a specific temperature and environmental range, such as protecting it from light and moisture. This documentation also sets the overall shelf-life and any in-use stability period after the first opening. Disposal must follow local pharmaceutical waste regulations, typically requiring return to a pharmacy or an authorized take-back program.